Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma
Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy al...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMJ Publishing Group
2020-10-01
|
| Series: | Journal for ImmunoTherapy of Cancer |
| Online Access: | https://jitc.bmj.com/content/8/2/e000668.full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1846172565334130688 |
|---|---|
| author | Marco Donia Rikke Andersen Troels Holz Borch Özcan Met Eva Ellebaek Inge Marie Svane |
| author_facet | Marco Donia Rikke Andersen Troels Holz Borch Özcan Met Eva Ellebaek Inge Marie Svane |
| author_sort | Marco Donia |
| collection | DOAJ |
| description | Personalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy almost fully to immune CPI. Still, the majority of patients fail to benefit from CPI treatment, raising the intriguing question on how TIL therapy may fit into the changing landscape of melanoma treatment. We took advantage of data from a unique cohort of patients with MM treated with T-cell therapy in consecutive clinical trials at our institution across the last 10 years. Based on detailed data on patient characteristics, pre-TIL and post-TIL treatments and long-term follow-up, we were able to address the important issue of how TIL therapy can be positioned in the current CPI era. We found that previous progression on anticytotoxic T-lymphocyte-associated protein 4 do not seem to harm neither rate nor duration of response to TIL therapy. Importantly, even in the hard-to-treat population of patients who progressed on antiprogrammed cell death protein 1 (anti-PD-1), an objective response rate of 32% was achieved, including durable responses. Yet, median progression-free survival was reduced in this anti-PD-1 refractory population. Trial registration number: ClinicalTrials.gov ID: NCT00937625, NCT02379195 and NCT02354690. |
| format | Article |
| id | doaj-art-0283487c583b4f2dad1a44097f01e3a7 |
| institution | Kabale University |
| issn | 2051-1426 |
| language | English |
| publishDate | 2020-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | Journal for ImmunoTherapy of Cancer |
| spelling | doaj-art-0283487c583b4f2dad1a44097f01e3a72024-11-09T19:15:11ZengBMJ Publishing GroupJournal for ImmunoTherapy of Cancer2051-14262020-10-018210.1136/jitc-2020-000668Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanomaMarco Donia0Rikke Andersen1Troels Holz Borch2Özcan Met3Eva Ellebaek4Inge Marie Svane5National Center for Cancer Immune Therapy, Department of Oncology, Herlev University Hospital, Herlev, DenmarkTechnical University of Denmark, Kongens Lyngby, DenmarkDepartment of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Herlev, Denmark1 National Center for Cancer Immune Therapy, Department of Oncology, Herlev Hospital, Herlev, Denmark7Department of Oncology, National Center for Cancer Immune Therapy (CCIT-DK), Copenhagen University Hospital, Herlev, DenmarkDepartment of Oncology, Copenhagen University Hospital, National Center for Cancer Immune Therapy (CCIT-DK), Herlev, DenmarkPersonalized cell therapy targeting tumor antigens with expanded tumor-infiltrating lymphocytes (TILs) has shown great promise in metastatic melanoma (MM) since the 90s. However, MM was first-in line to benefit from the wave of checkpoint inhibitors (CPI), which shifted the focus of immunotherapy almost fully to immune CPI. Still, the majority of patients fail to benefit from CPI treatment, raising the intriguing question on how TIL therapy may fit into the changing landscape of melanoma treatment. We took advantage of data from a unique cohort of patients with MM treated with T-cell therapy in consecutive clinical trials at our institution across the last 10 years. Based on detailed data on patient characteristics, pre-TIL and post-TIL treatments and long-term follow-up, we were able to address the important issue of how TIL therapy can be positioned in the current CPI era. We found that previous progression on anticytotoxic T-lymphocyte-associated protein 4 do not seem to harm neither rate nor duration of response to TIL therapy. Importantly, even in the hard-to-treat population of patients who progressed on antiprogrammed cell death protein 1 (anti-PD-1), an objective response rate of 32% was achieved, including durable responses. Yet, median progression-free survival was reduced in this anti-PD-1 refractory population. Trial registration number: ClinicalTrials.gov ID: NCT00937625, NCT02379195 and NCT02354690.https://jitc.bmj.com/content/8/2/e000668.full |
| spellingShingle | Marco Donia Rikke Andersen Troels Holz Borch Özcan Met Eva Ellebaek Inge Marie Svane Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma Journal for ImmunoTherapy of Cancer |
| title | Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma |
| title_full | Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma |
| title_fullStr | Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma |
| title_full_unstemmed | Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma |
| title_short | Future role for adoptive T-cell therapy in checkpoint inhibitor-resistant metastatic melanoma |
| title_sort | future role for adoptive t cell therapy in checkpoint inhibitor resistant metastatic melanoma |
| url | https://jitc.bmj.com/content/8/2/e000668.full |
| work_keys_str_mv | AT marcodonia futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma AT rikkeandersen futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma AT troelsholzborch futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma AT ozcanmet futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma AT evaellebaek futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma AT ingemariesvane futureroleforadoptivetcelltherapyincheckpointinhibitorresistantmetastaticmelanoma |